HLB bioStep Co.,Ltd.

Equities

A278650

KR7278650007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
2,555 ^KRW	-2.11%		-22.46%	-17.31%

May. 20	HLB bioStep Co.,Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	CI
May. 20	HLB bioStep Co.,Ltd. authorizes a Buyback Plan.	CI

Tranche Update on KNOTUS Co.,Ltd's Equity Buyback Plan announced on March 13, 2020.

September 14, 2020 at 01:19 am EDT

From April 1, 2020 to June 30, 2020, the company has repurchased 9,136 shares, representing 0.01% for KRW 171.26 million. With this, the company has completed the repurchase of 69,714 shares, representing 0.11% for KRW 918.87 million under the buyback announced on March 13, 2020.

Latest news about HLB bioStep Co.,Ltd.

HLB bioStep Co.,Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	May. 20	CI
HLB bioStep Co.,Ltd. authorizes a Buyback Plan.	May. 19	CI
Tranche Update on HLB bioStep Co.,Ltd.'s Equity Buyback Plan announced on February 8, 2024.	May. 17	CI
HLB bioStep Co.,Ltd. announced that it expects to receive KRW 1.438165744 billion in funding from Kangstem Biotech Co., Ltd.	Apr. 24	CI
Tranche Update on HLB bioStep Co.,Ltd.'s Equity Buyback Plan announced on December 4, 2023.	Mar. 08	CI
HLB bioStep Co.,Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.	Feb. 08	CI
HLB bioStep Co.,Ltd. authorizes a Buyback Plan.	Feb. 07	CI
HLB bioStep Co.,Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	Dec. 04	CI
HLB bioStep Co.,Ltd. authorizes a Buyback Plan.	Dec. 03	CI
Panagene Inc. announced that it expects to receive KRW 56.599994061 billion in funding from a group of investors	23-06-20	CI
Panagene Inc. announced that it expects to receive KRW 46.068324061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.	23-06-20	CI
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors	23-03-12	CI
HLB SCIENCE Inc. announced that it has received KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	23-02-08	CI
HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	23-01-31	CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors	23-01-31	CI
KNOTUS Co.,Ltd's Equity Buyback announced on March 13, 2020 has expired with 71,714 shares, representing 0.98% for KRW 960.15 million.	22-03-11	CI
KNOTUS Co.,Ltd announced that it has received KRW 81.1 billion in funding	22-01-12	CI
HLB Co., Ltd. entered into a contract to acquire 18.4% stake in KNOTUS Co.,Ltd from Jeong In-seong and Kim Do-hyung for KRW 56.2 billion.	21-12-26	CI
KNOTUS Co.,Ltd announced that it expects to receive KRW 94.6 billion in funding	21-12-26	CI
KNOTUS Co.,Ltd(KOSDAQ:A278650) added to S&P Global BMI Index	21-09-20	CI
Tranche Update on KNOTUS Co.,Ltd's Equity Buyback Plan announced on March 13, 2020.	21-06-14	CI
Tranche Update on KNOTUS Co.,Ltd's Equity Buyback Plan announced on March 13, 2020.	21-06-14	CI
KNOTUS Co.,Ltd's Equity Buyback Plan Extended till March 12, 2022.	21-03-11	CI
Tranche Update on KNOTUS Co.,Ltd's Equity Buyback Plan announced on March 13, 2020.	20-12-13	CI
Tranche Update on KNOTUS Co.,Ltd's Equity Buyback Plan announced on March 13, 2020.	20-09-14	CI

Chart HLB bioStep Co.,Ltd.

Duration

Period

More charts

Company Profile

HLB bioStep Co Ltd, formerly KNOTUS Co Ltd, is a Korea-based company mainly engaged in non-clinical trial business. The Company operates through three segments. The Non-clinical Test Consignment Agency Business segment conducts non-clinical is mainly engaged in the test on newly developed substances such as new drugs ,and tests the efficacy and pharmacodynamics of substances. In addition, this segment is engaged in the test of the safety of substances. The Bioinfra Business segment is engaged in animal laboratory design, construction, and maintenance. In addition, this segment provides equipment delivery. The Pet Medical Business segment is engaged in the development of veterinary medicine and the sale of companion animal products.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
HLB BIOSTEP CO.,LTD.	-17.31%	160M
EXACT SCIENCES CORPORATION	-31.83%	9.87B
GUARDANT HEALTH, INC.	-16.78%	2.75B
BGI GENOMICS CO., LTD.	-15.31%	2.13B
VERACYTE, INC.	-24.06%	1.65B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+67.33%	1.47B
CAREDX, INC	+28.83%	811M
SEEGENE, INC.	-5.02%	733M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-31.63%	510M
CURIOX BIOSYSTEMS CO., LTD	+1.59%	300M

Bio Diagnostics & Testing